Vehicle + LDE225 0.25% + LDE225 0.75%
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Conditions
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Trial Timeline
Jul 1, 2009 → —
NCT ID
NCT00961896About Vehicle + LDE225 0.25% + LDE225 0.75%
Vehicle + LDE225 0.25% + LDE225 0.75% is a phase 2 stage product being developed by Novartis for Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00961896. Target conditions include Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients.
What happened to similar drugs?
3 of 20 similar drugs in Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients were approved
Approved (3) Terminated (3) Active (14)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00961896 | Phase 2 | Completed |
Competing Products
20 competing products in Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients